Koers Krebs Biochemicals & Industries Limited
Aandelen
KREBSBIO
INE268B01013
Farmaceutische producten
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
70,11 INR | -2,54% | +1,17% | -10,51% |
Omzet 2022 | 587 mln. 7,03 mln. 6,61 mln. | Omzet 2023 | 521 mln. 6,25 mln. 5,87 mln. | Marktkapitalisatie | 1,22 mld. 14,57 mln. 13,7 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -445 mln. -5,33 mln. -5,01 mln. | Nettowinst (verlies) 2023 | -247 mln. -2,96 mln. -2,78 mln. | EV/omzet 2022 | 7,71 x |
Nettoschuld 2022 | 1,43 mld. 17,13 mln. 16,11 mln. | Nettoschuld 2023 | 1,83 mld. 21,96 mln. 20,65 mln. | EV/omzet 2023 | 5,85 x |
K/w-verhouding 2022 |
-6,94
x | K/w-verhouding 2023 |
-4,92
x | Werknemers | 210 |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 22,45% |
1 dag | -2,54% | ||
1 week | +1,17% | ||
Lopende maand | +14,90% | ||
1 maand | +7,84% | ||
3 maanden | -6,66% | ||
6 maanden | -11,19% | ||
Lopend jaar | -10,51% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jitendra Shah
CEO | Chief Executive Officer | - | 09-11-21 |
Founder | 74 | 02-12-91 | |
Ritesh Jain
DFI | Director of Finance/CFO | - | 03-02-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 67 | 26-09-00 | |
Founder | 74 | 02-12-91 | |
Avinash Ravi
BRD | Director/Board Member | 45 | 01-01-02 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
19-04-24 | 70,11 | -2,54% | 54 |
18-04-24 | 71,94 | +0,42% | 326 |
16-04-24 | 71,64 | +3,38% | 795 |
15-04-24 | 69,3 | -1,74% | 1 943 |
10-04-24 | 70,53 | -3,38% | 481 |
uitgestelde koers Bombay S.E., 19 april 2024 om 07:24 uur
Meer koersenVaira. 1 jan. | Kapi. | |
---|---|---|
-10,51% | 18,56 mln. | |
+19,62% | 43,54 mld. | |
+17,02% | 21,74 mld. | |
+8,36% | 13,02 mld. | |
+6,06% | 13,53 mld. | |
+34,21% | 11,28 mld. | |
-10,69% | 6,99 mld. | |
-0,05% | 6,79 mld. | |
-8,87% | 5,73 mld. | |
+7,71% | 5,09 mld. |